Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 2, 2008, Pages 291-296

  Bach, J ^a   Endler, G ^b   Winkelmann, B R ^c   Boehm, B O ^d   Maerz, W ^e   Mannhalter, C ^b   Hellstern, Peter ^a  

^a Academic City Hospital   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Cardiology Group Frankfurt Sachsenhausen   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e SYNLAB ACADEMY   (Germany)

Author keywords

Acute coronary syndromes; Coronary heart disease; Factor XII; Factor XII polymorphism; Factor XIIa

Indexed keywords

BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; CYTOSINE; THYMINE;

ACUTE CORONARY SYNDROME; ADULT; AGE DISTRIBUTION; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENDER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HOSPITAL PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; WILD TYPE;

AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; CORONARY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FACTOR XII; FACTOR XII DEFICIENCY; FACTOR XIIA; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERMANY; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK;

EID: 38349171226     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02839.x     Document Type: Article

References (32)

1. Braat EA, Dooijewaard G, Rijken DC. Fibrinolytic properties of activated FXII. Eur J Biochem 1999; 263: 904-11.
2. Endler G, Marsik C, Jilma B, Schickauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between FXII activity and overall survival. J Thromb Haemost 2007; 5: 1143-8.
3. Gailani D, Renne T. The intrinsic pathway of coagulation: A target for treating thromboembolic disease? J Thromb Haemost 2007; 5: 1106-12.
4. von Kanel R, Wuillemin WA, Furlan M, Lämmle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis 1992; 3: 555-61.
5. Zeerleder S, Schloesser M, Redondo M, Wuillemin WA, Engel W, Furlan M, Lämmle B. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency -a study on 73 subjects from 14 Swiss families. Thromb Haemost 1999; 82: 1240-6.
6. Lämmle B, Wuillemin WA, Huber I, Krauskopf M, Zurcher C, Pflugshaupt R, Furlan M. Thromboembolism and bleeding tendency in congenital factor XII deficiency -a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65: 117-21.
7. Girolami A, Morello M, Girolami B, Lombardi AM, Bertolo C. Myocardial infarction and arterial thrombosis in severe (homozygous) FXII deficiency: No apparent causative relation. Clin Appl Thromb Hemost 2005; 11: 49-53.
8. Bertina RM, Poort SR, Rosendaal FR. The 46C>T polymorphism in the factor XII gene (F12) and the risk of venous thrombosis. J Thromb Haemost 2005; 3: 587-9.
9. Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 1992; 68: 285-90.
10. Coppola R, Cristilli P, Cugno M, Ariens RA, Mari D, Mannucci PM. Measurement of activated factor XII in health and disease. Blood Coagul Fibrinolysis 1996; 7: 530-5.
11. Kohler HP, Carter AM, Stickland MH, Grant PJ. Levels of activated FXII in survivors of myocardial infarction - association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998; 79: 14-8.
12. Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 2103-6.
13. Grundt H, Nilsen DW, Hetland O, Valente E, Fagertun HE. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 2004; 147: 260-6.
14. Kelleher CC, Mitropoulos KA, Imeson J, Meade TW, Martin JC, Reeves BE, Hughes LO. Hageman factor and risk of myocardial infarction in middle-aged men. Atherosclerosis 1992; 97: 67-73.
15. Colhoun HM, Zito F, Norman CN, Rubens MB, Fuller JH, Humphries SE. Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 2002; 163: 363-9.
16. Lowe GDO, Rumley A, McMahon AD, Ford I, O'Reilly DSJ, Packard CJ. Interleukin-6, Fibrin D-Dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. ATVB 2004; 24: 1529-34.
17. Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987; 15: 8125-48.
18. Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N, Niho Y. A common genetic polymorphism (46 C to T substitution) in the 5'- untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-4.
19. Endler G, Exner M, Mannhalter C, Meier S, Ruzicka K, Handler S, Panzer S, Wagner O, Quehenberger P. A common C>T polymorphism at nt 46 in the promoter region of coagulation factor XII is associated with decreased factor XII activity. Thromb Res 2001; 101: 255-60.
20. Kohler HP, Futers TS, Grant PJ. FXII (46C>T) polymorphism and in vivo generation of FXII activity-gene frequencies and relationship in patients with coronary artery disease. Thromb Haemost 1999; 81: 745-7.
21. Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE, Miller GJ. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation 2000; 102: 2058-62.
22. Govers-Riemslag JWP, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE, Hamulyak K, Spronk HMA, Miller GJ, ten Cate H. The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost 2007; 5: 1896-903.
23. Endler G, Mannhalter C, Sunder-Plassmann H, Lalouschek W, Kapiotis S, Exner M, Jordanova N, Meier S, Kunze F, Wagner O, Huber K. Homozygosity for the C>T polymorphism at nucleotide 46 in the 5'untranslated region of the factor XII gene protects from development of acute coronary syndrome. Br J Haematol 2001; 115: 1007-9.
24. Zito F, Lowe G, Rumley A, McMahon A, Humphries S. Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis 2002; 165: 153.
25. Santamaria A, Martinez-Rubio A, Mateo J, Tirado I, Soria JM, Fontcuberta J. Homozygosity of the T allele of the 46C-T polymorphism in the F12 gene is a risk factor for acute coronary artery disease in the Spanish population. Haematologica 2004; 89: 878-9.
26. Roldan V, Corral J, Marin F, Pineda J, Vicente V, Gonzalez-Conejero R. Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. Thromb Haemost 2005; 94: 1294-9.
27. Winkelmann BR, Maerz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J. Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001; 2: S1-73.
28. Soria JM, Almasy L, Souto JC, Delphine B, Buil A, Faure A, Martinez-Marchan E, Mateo J, Borrell M, Stone W, Lathrop M, Fontcuberta J, Blangero J. A quantitative-trait locus in the human FXII gene influences both plasma factor XII levels and susceptibility to thrombotic disease. Am J Hum Genet 2002; 70: 567-74.
29. Gordon EM, Johnson TR, Ramos LP, Schmeidler-Sapiro KT. Enhanced expression of factor XII (Hageman factor) in isolated livers of estrogen- and prolactin-treated rats. J Lab Clin Med 1991; 117: 353-8.
30. Citarella F, Misiti S, Felici A, Farsetti A, Pontecorvi A, Fantoni A. Estrogen induction and contact phase activation of human factor XII. Steroids 1996; 61: 270-6.
31. Doggen CJM, Rosendaal FR, Meijers CM. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-51.
32. Citarella F, Felici A, Brouwer M, Wagstaff J, Fantoni A, Hack CE. Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood 1997; 90: 1501-7.